BRAF and thyroid gland carcinoma: For these patients, the most common treatment options are represented by kinase inhibitor-based therapies that target different kinases, such as RET, BRAF, RAS, MAPK, and PI3K, constitutively activated in thyroid cancer cells as a consequence of specific genetic alterations.